Restatement of Previously Issued Financial Statements - Schedule of Restatement of Previously Issued Financial Statements - Condensed Consolidated Cash flows (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net Income (Loss)	$ 16,923	$ 40,405	$ 52,046	$ 137,230
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization			51,295	36,605
Amortization of debt issuance costs			1,373
Stock-based compensation	6,373	6,154	19,110	21,054
Deferred income taxes, net			(9,268)	1,722
Contingent consideration	(34,292)	(2,309)	(31,266)	(11,604)
Non-cash interest income			(2,023)	0
Operating lease right of use asset amortization			10,203	5,672
Other			1,275	210
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable			8,315	(8,609)
Inventories			25,979	(64,308)
Prepaid expenses and other assets			(12,749)	168
Other assets			(707)	(298)
Accounts payable			(8,619)	(10,124)
Accrued expenses			(12,514)	3,043
Operating lease liabilities			(7,676)	(1,548)
Long-term liabilities			79	(372)
Total cash provided by operating activities			84,853	110,201
Cash flows from investing activities:
Acquisitions, net of cash acquired			(27,843)	0
Proceeds from maturity of marketable securities held to maturity			102,323	0
Additions to capitalized software costs			(2,736)	(2,568)
Purchases of property, plant and equipment			(25,135)	(64,390)
Purchase of intellectual property			0	(45,000)
Other investing activities			21	30
Total cash provided by (used in) investing activities			46,630	(111,928)
Cash flows from financing activities:
Proceeds from exercise of stock options			356	2,784
Payment of tax withholding obligation on vesting of restricted stock			(12,178)	(15,829)
Repayment of Convertible Senior Notes			(33)	(18)
Payment of earnout consideration			(7,298)	0
Proceeds from issuance of common stock, net			(13)	0
Total cash used in financing activities			(19,166)	(13,063)
Effect of exchange rate changes on cash and cash equivalents			(4,996)	(15,661)
Net increase (decrease) in cash and cash equivalents			107,321	(30,451)
Cash, cash equivalents and restricted cash, beginning of period			523,458	603,814
Cash and cash equivalents, end of period	630,779	$ 573,363	630,779	573,363
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases			1,129	25,705
FlexBiosys, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of 31,415 shares of common stock issued for the acquisition of FlexBiosys, Inc.			5,465	0
Avitide, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of 42,621 shares of common stock issued for the Avitide, Inc. contingent consideration earnout			7,229
As Previously Reported
Cash flows from operating activities:
Net Income (Loss)	18,172		67,065
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization			50,942
Amortization of debt issuance costs			1,373
Stock-based compensation			19,110
Deferred income taxes, net			(9,756)
Contingent consideration	(34,292)		(31,266)
Non-cash interest income			(2,023)
Operating lease right of use asset amortization			10,203	(22,033)
Other			861
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable			8,315
Inventories			25,979
Prepaid expenses and other assets			(10,733)
Other assets			(707)
Accounts payable			(8,619)
Accrued expenses			(28,294)
Operating lease liabilities			(7,676)	26,157
Long-term liabilities			79
Total cash provided by operating activities			84,853	110,201
Cash flows from investing activities:
Acquisitions, net of cash acquired			(27,843)
Proceeds from maturity of marketable securities held to maturity			102,323
Additions to capitalized software costs			(2,736)
Purchases of property, plant and equipment			(25,135)
Purchase of intellectual property			0
Other investing activities			21
Total cash provided by (used in) investing activities			46,630
Cash flows from financing activities:
Proceeds from exercise of stock options			356
Payment of tax withholding obligation on vesting of restricted stock			(12,178)
Repayment of Convertible Senior Notes			(33)
Payment of earnout consideration			(7,298)
Proceeds from issuance of common stock, net			(13)
Total cash used in financing activities			(19,166)
Effect of exchange rate changes on cash and cash equivalents			(4,996)
Net increase (decrease) in cash and cash equivalents			107,321
Cash, cash equivalents and restricted cash, beginning of period			523,458
Cash and cash equivalents, end of period	630,779		630,779
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases			1,129
As Previously Reported | FlexBiosys, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of 31,415 shares of common stock issued for the acquisition of FlexBiosys, Inc.			5,465
As Previously Reported | Avitide, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of 42,621 shares of common stock issued for the Avitide, Inc. contingent consideration earnout			7,229
Revenue Adjustments
Cash flows from operating activities:
Net Income (Loss)	(1,053)		(14,431)
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization			0
Amortization of debt issuance costs			0
Stock-based compensation			0
Deferred income taxes, net			667
Contingent consideration	0		0
Non-cash interest income			0
Operating lease right of use asset amortization			0
Other			0
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable			0
Inventories			0
Prepaid expenses and other assets			(2,016)
Other assets			0
Accounts payable			0
Accrued expenses			15,780
Operating lease liabilities			0
Long-term liabilities			0
Total cash provided by operating activities			0
Cash flows from investing activities:
Acquisitions, net of cash acquired			0
Proceeds from maturity of marketable securities held to maturity			0
Additions to capitalized software costs			0
Purchases of property, plant and equipment			0
Purchase of intellectual property			0
Other investing activities			0
Total cash provided by (used in) investing activities			0
Cash flows from financing activities:
Proceeds from exercise of stock options			0
Payment of tax withholding obligation on vesting of restricted stock			0
Repayment of Convertible Senior Notes			0
Payment of earnout consideration			0
Proceeds from issuance of common stock, net			0
Total cash used in financing activities			0
Effect of exchange rate changes on cash and cash equivalents			0
Net increase (decrease) in cash and cash equivalents			0
Cash, cash equivalents and restricted cash, beginning of period			0
Cash and cash equivalents, end of period	0		0
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases			0
Revenue Adjustments | FlexBiosys, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of 31,415 shares of common stock issued for the acquisition of FlexBiosys, Inc.			0
Revenue Adjustments | Avitide, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of 42,621 shares of common stock issued for the Avitide, Inc. contingent consideration earnout			0
Other Adjustments
Cash flows from operating activities:
Net Income (Loss)	(196)		(588)
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization			353
Amortization of debt issuance costs			0
Stock-based compensation			0
Deferred income taxes, net			(179)
Contingent consideration	0		0
Non-cash interest income			0
Operating lease right of use asset amortization			0	27,705
Other			414
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable			0
Inventories			0
Prepaid expenses and other assets			0
Other assets			0
Accounts payable			0
Accrued expenses			0
Operating lease liabilities			0	(27,705)
Long-term liabilities			0
Total cash provided by operating activities			0	$ 0
Cash flows from investing activities:
Acquisitions, net of cash acquired			0
Proceeds from maturity of marketable securities held to maturity			0
Additions to capitalized software costs			0
Purchases of property, plant and equipment			0
Purchase of intellectual property			0
Other investing activities			0
Total cash provided by (used in) investing activities			0
Cash flows from financing activities:
Proceeds from exercise of stock options			0
Payment of tax withholding obligation on vesting of restricted stock			0
Repayment of Convertible Senior Notes			0
Payment of earnout consideration			0
Proceeds from issuance of common stock, net			0
Total cash used in financing activities			0
Effect of exchange rate changes on cash and cash equivalents			0
Net increase (decrease) in cash and cash equivalents			0
Cash, cash equivalents and restricted cash, beginning of period			0
Cash and cash equivalents, end of period	$ 0		0
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases			0
Other Adjustments | FlexBiosys, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of 31,415 shares of common stock issued for the acquisition of FlexBiosys, Inc.			0
Other Adjustments | Avitide, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of 42,621 shares of common stock issued for the Avitide, Inc. contingent consideration earnout			$ 0